Advanced Cancer

HGS-ETR2 trials demonstrate safety, tolerability in advanced cancer patients

Published in Biotech Business Week, October 18th, 2004

Human Genome Sciences, Inc., (HGSI) announced that the initial results of an ongoing phase I clinical trial demonstrate the safety and tolerability of HGS-ETR2 (agonistic human monoclonal antibody to TRAIL Receptor 2) in cancer patients with advanced solid tumors and support continued dose escalation and evaluation of HGS-ETR2 in these patients.

Safety, pharmacokinetic, and biological activity data from the phase I study were presented at the 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Geneva, Switzerland.

The conference is organized jointly by the European Organization for Research and Treatment of Cancer, (EORTC)...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week

Source: Biotech Business Week (2004-10-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry